Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Dermatology"
DOI: 10.1111/bjd.20602
Abstract: Current psoriasis therapies have little-to-no effect on comorbidities such as obesity and chronic obstructive pulmonary disease (COPD). Apremilast, a phosphodiesterase 4 (PDE-4) inhibitor, is approved for moderate-to-severe psoriasis and considered a safe treatment option, that… read more here.
Keywords: complete clearance; psoriasis; severe plaque; roflumilast therapy ... See more keywords